Elute Inc, a US-based developer of drug-eluting device technology for controlled and extended drug release, on Tuesday announced a strategic partnership with Spartan Medical Inc, a Service-Disabled Veteran-Owned and operated medical solutions company serving the Department of Veterans Affairs (VA), Department of Defense (DoD), civilian hospitals, and Ambulatory Surgery Centers (ASCs) nationwide.
This partnership will expand access to Elute's BonVie+ bone graft substitute to physicians and patients at VA and DoD medical facilities worldwide.
Bone graft substitutes are used to fill bone voids caused by trauma or infection. Traditional options such as bone cement and calcium sulphate-based granules can have significant drawbacks, Elute explained. Bone cement is non-biodegradable, does not support new bone growth, and often requires a second surgery for removal. Calcium sulphate substitutes resorb naturally but can cause fluid buildup (seromas) and wound drainage.
BonVie+ was developed to overcome these challenges. The implant gradually resorbs while being replaced by the patient's own healthy bone, creating a more natural and predictable path to healing.
Abbott secures CE Mark for Cologuard Plus in Europe
VibroSense Dynamics secures Thai regulatory approval for VibroSense Meter II
SciBase technology selected as primary endpoint in NIH-led skin exposure study
TWINBIRD launches portable freezer targeting dry-ice-free research cold chains
Urolution Medical secures FDA clearance for OpenFlo urinary catheter
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
Okami Medical receives FDA approval for expanded indication of LOBO Vascular Occluder
Oxurion in talks to acquire Eclevar's MedTech CRO business and assets
FDA Advisory Committee votes in favour of GRAIL's Galleri multi-cancer early detection test
Insmed's ARIKAYCE sNDA granted priority review by FDA
ProBio and Kun Tuo collaborate to deliver integrated CDMO-CRO solutions for advanced therapies
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase